Brain Cancer: Medical Treatments
The question
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 27 October 2025 to Question 77609 on Medical Treatments: Cost Effectiveness, what percentage of completed NICE appraisals for brain tumour medications have led to approval for use of a medication by the NHS in the last 12 months.
Answered by Dr Zubir Ahmed
The National Institute for Health and Care Excellence (NICE) has not published final guidance on any brain tumour appraisals in the last 12 months.
NICE is currently developing guidance on the use of vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and over and recently consulted on its draft recommendations. NICE currently expects to publish final guidance in January 2026.
Verbatim has judged this answer against the question that was actually asked — answered, partly answered, or evaded. Sign in to see the verdict →